Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback